Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review

AIM: To investigate the efficacy(survival) and safety of treatments for recurrent hepatocellular carcinoma(HCC) in liver transplantation(LT) patients.METHODS: Literature search was performed on available online databases without a time limit until January 2015. Clinical studies describing survival a...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 21; no. 39; pp. 11185 - 11198
Main Authors de'Angelis, Nicola, Landi, Filippo, Carra, Maria Clotilde, Azoulay, Daniel
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 21.10.2015
Subjects
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - secondary
Carcinoma, Hepatocellular - surgery
carcinoma;Liver
hepatocellular
Humans
Liver Neoplasms - mortality
Liver Neoplasms - pathology
Liver Neoplasms - surgery
Liver Transplantation - adverse effects
Liver Transplantation - mortality
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - therapy
Niacinamide - adverse effects
Niacinamide - analogs & derivatives
Niacinamide - therapeutic use
Phenylurea Compounds - adverse effects
Phenylurea Compounds - therapeutic use
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Recurrent
Reoperation
Risk Factors
Survival Analysis
Systematic Reviews
Time Factors
transplan
Treatment Outcome
Trans-arterial chemoembolization
Tumor recurrence
Sorafenib
Recurrent hepatocellular carcinoma
Surgical resection
Systematic review
Liver transplantation
Online AccessGet full text

Cover

Abstract AIM: To investigate the efficacy(survival) and safety of treatments for recurrent hepatocellular carcinoma(HCC) in liver transplantation(LT) patients.METHODS: Literature search was performed on available online databases without a time limit until January 2015. Clinical studies describing survival after HCC recurrence in LT patients were retrieved for a fulltext evaluation. A total of 61 studies were selected: 13 case reports, 41 retrospective case series, and 7 retrospective comparative studies.RESULTS: Based on all included studies, the mean HCC recurrence rate was 16% of all LTs for HCC. A total of 1021 LT patients experienced HCC recurrence. The median time from LT to HCC recurrence was 13 mo(range 2-132 mo). The majority of patients(67%) presented with HCC extra-hepatic recurrences, involving lung, bone, adrenal gland, peritoneal lymph nodes, and rarely the brain. Overall survival after HCC recurrence was 12.97 mo. Surgical resection of localized HCC recurrence and Sorafenib for controlling systemic spread of HCC recurrence were associated with the higher survival rates(42 and 18 mo, res-pectively). However, Sorafenib, especially when combined with m TOR, was frequently associated with severe side effects that required dose reduction or discontinuation CONCLUSION: Management of recurrent HCC in LT patients is challenging and associated with poor prognosis independently of the type of treatment.
AbstractList AIMTo investigate the efficacy (survival) and safety of treatments for recurrent hepatocellular carcinoma (HCC) in liver transplantation (LT) patients.METHODSLiterature search was performed on available online databases without a time limit until January 2015. Clinical studies describing survival after HCC recurrence in LT patients were retrieved for a full-text evaluation. A total of 61 studies were selected: 13 case reports, 41 retrospective case series, and 7 retrospective comparative studies.RESULTSBased on all included studies, the mean HCC recurrence rate was 16% of all LTs for HCC. A total of 1021 LT patients experienced HCC recurrence. The median time from LT to HCC recurrence was 13 mo (range 2-132 mo). The majority of patients (67%) presented with HCC extra-hepatic recurrences, involving lung, bone, adrenal gland, peritoneal lymph nodes, and rarely the brain. Overall survival after HCC recurrence was 12.97 mo. Surgical resection of localized HCC recurrence and Sorafenib for controlling systemic spread of HCC recurrence were associated with the higher survival rates (42 and 18 mo, respectively). However, Sorafenib, especially when combined with mTOR, was frequently associated with severe side effects that required dose reduction or discontinuationCONCLUSIONManagement of recurrent HCC in LT patients is challenging and associated with poor prognosis independently of the type of treatment.
AIM: To investigate the efficacy (survival) and safety of treatments for recurrent hepatocellular carcinoma (HCC) in liver transplantation (LT) patients. METHODS: Literature search was performed on available online databases without a time limit until January 2015. Clinical studies describing survival after HCC recurrence in LT patients were retrieved for a full-text evaluation. A total of 61 studies were selected: 13 case reports, 41 retrospective case series, and 7 retrospective comparative studies. RESULTS: Based on all included studies, the mean HCC recurrence rate was 16% of all LTs for HCC. A total of 1021 LT patients experienced HCC recurrence. The median time from LT to HCC recurrence was 13 mo (range 2-132 mo). The majority of patients (67%) presented with HCC extra-hepatic recurrences, involving lung, bone, adrenal gland, peritoneal lymph nodes, and rarely the brain. Overall survival after HCC recurrence was 12.97 mo. Surgical resection of localized HCC recurrence and Sorafenib for controlling systemic spread of HCC recurrence were associated with the higher survival rates (42 and 18 mo, respectively). However, Sorafenib, especially when combined with mTOR, was frequently associated with severe side effects that required dose reduction or discontinuation CONCLUSION: Management of recurrent HCC in LT patients is challenging and associated with poor prognosis independently of the type of treatment.
AIM: To investigate the efficacy(survival) and safety of treatments for recurrent hepatocellular carcinoma(HCC) in liver transplantation(LT) patients.METHODS: Literature search was performed on available online databases without a time limit until January 2015. Clinical studies describing survival after HCC recurrence in LT patients were retrieved for a fulltext evaluation. A total of 61 studies were selected: 13 case reports, 41 retrospective case series, and 7 retrospective comparative studies.RESULTS: Based on all included studies, the mean HCC recurrence rate was 16% of all LTs for HCC. A total of 1021 LT patients experienced HCC recurrence. The median time from LT to HCC recurrence was 13 mo(range 2-132 mo). The majority of patients(67%) presented with HCC extra-hepatic recurrences, involving lung, bone, adrenal gland, peritoneal lymph nodes, and rarely the brain. Overall survival after HCC recurrence was 12.97 mo. Surgical resection of localized HCC recurrence and Sorafenib for controlling systemic spread of HCC recurrence were associated with the higher survival rates(42 and 18 mo, res-pectively). However, Sorafenib, especially when combined with m TOR, was frequently associated with severe side effects that required dose reduction or discontinuation CONCLUSION: Management of recurrent HCC in LT patients is challenging and associated with poor prognosis independently of the type of treatment.
To investigate the efficacy (survival) and safety of treatments for recurrent hepatocellular carcinoma (HCC) in liver transplantation (LT) patients. Literature search was performed on available online databases without a time limit until January 2015. Clinical studies describing survival after HCC recurrence in LT patients were retrieved for a full-text evaluation. A total of 61 studies were selected: 13 case reports, 41 retrospective case series, and 7 retrospective comparative studies. Based on all included studies, the mean HCC recurrence rate was 16% of all LTs for HCC. A total of 1021 LT patients experienced HCC recurrence. The median time from LT to HCC recurrence was 13 mo (range 2-132 mo). The majority of patients (67%) presented with HCC extra-hepatic recurrences, involving lung, bone, adrenal gland, peritoneal lymph nodes, and rarely the brain. Overall survival after HCC recurrence was 12.97 mo. Surgical resection of localized HCC recurrence and Sorafenib for controlling systemic spread of HCC recurrence were associated with the higher survival rates (42 and 18 mo, respectively). However, Sorafenib, especially when combined with mTOR, was frequently associated with severe side effects that required dose reduction or discontinuation Management of recurrent HCC in LT patients is challenging and associated with poor prognosis independently of the type of treatment.
Author Nicola de’Angelis Filippo Landi Maria Clotilde Carra Daniel Azoulay
AuthorAffiliation Unit of Digestive, Hepato-Pancreato-Biliary Surgery, and Liver Transplantation, Henri-Mondor Hospital Inserm, Unité 4394-MACBEth, 94010 Créteil, France Department of Advanced Biomedical Sciences, University Federico Ⅱ of Naples University Paris 7, Denis Diderot, Rothschild Hospital Inserm, Unité 955-IMRB, 94010 Créteil, France
Author_xml – sequence: 1
  givenname: Nicola
  surname: de'Angelis
  fullname: de'Angelis, Nicola
– sequence: 2
  givenname: Filippo
  surname: Landi
  fullname: Landi, Filippo
– sequence: 3
  givenname: Maria Clotilde
  surname: Carra
  fullname: Carra, Maria Clotilde
– sequence: 4
  givenname: Daniel
  surname: Azoulay
  fullname: Azoulay, Daniel
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26494973$$D View this record in MEDLINE/PubMed
BookMark eNpVkU1v1DAQhi1URLeFH8AF5cgli8cfccwBqaqAViriAmfLcSZZV4m9tbNb9d_XS5cV-GBrxu-8M_ZzQc5CDEjIe6BrrkT76fF-XO8ZrD3XawBo5SuyYgx0zVpBz8gKKFW15kydk4uc7yllnEv2hpyzRmihFV-R7ocNdsQZw5KrOFQJ3S6lElUb3NolOpym3WRT5WxyPsTZVnZYMFWT35d9STbk7WTDYhcfw-fqqspPecG5hK6Y7T0-viWvBztlfHc8L8nvb19_Xd_Udz-_315f3dVOUr3Ug-4EoOp62rBB9rppqRAMSrIZrBJgB9GgA90y3mGvmKWMDU3PHCIIRxt-Sb68-G533Yy9K49IdjLb5Gebnky03vx_E_zGjHFvREOVhoPBx6NBig87zIuZfT58gA0Yd9mAYkpwLUEXKbxIXYo5JxxObYCaAxtT2JjCxhQ25g-bUvPh3_lOFX9hFAE_mm5iGB98GE8aTdvD0pKKVmjJJcjSRFIJ_BkmjaAG
CitedBy_id crossref_primary_10_1097_TP_0000000000003117
crossref_primary_10_16931_1995_5464_2019465_73
crossref_primary_10_1186_s12885_021_08714_7
crossref_primary_10_1016_j_hpb_2021_09_008
crossref_primary_10_2217_imt_2020_0014
crossref_primary_10_1097_CLD_0000000000000071
crossref_primary_10_4285_kjt_22_0054
crossref_primary_10_4251_wjgo_v15_i1_1
crossref_primary_10_1016_j_jhepr_2023_100965
crossref_primary_10_1155_2019_5796074
crossref_primary_10_1155_2019_2509059
crossref_primary_10_3389_fonc_2022_960808
crossref_primary_10_3748_wjg_v29_i15_2261
crossref_primary_10_1097_JS9_0000000000000806
crossref_primary_10_3390_jcm10020238
crossref_primary_10_1007_s00261_017_1323_0
crossref_primary_10_3390_cancers13194882
crossref_primary_10_1097_TXD_0000000000001086
crossref_primary_10_1097_TP_0000000000002955
crossref_primary_10_1016_j_trre_2021_100676
crossref_primary_10_1186_s12885_024_12322_6
crossref_primary_10_1111_ajt_15697
crossref_primary_10_4254_wjh_v15_i2_129
crossref_primary_10_1016_j_hbpd_2022_11_010
crossref_primary_10_1016_j_jhep_2020_11_026
crossref_primary_10_1097_SLA_0000000000001894
crossref_primary_10_1002_ags3_12316
crossref_primary_10_3390_cancers13071617
crossref_primary_10_1007_s12029_020_00498_6
crossref_primary_10_3390_cancers15123165
crossref_primary_10_1016_j_suc_2023_09_002
crossref_primary_10_1007_s12328_019_00934_6
crossref_primary_10_1007_s12328_019_01031_4
crossref_primary_10_1007_s12029_019_00252_7
crossref_primary_10_1007_s12029_021_00716_9
crossref_primary_10_1186_s12957_020_01873_0
crossref_primary_10_1016_j_aohep_2020_100294
crossref_primary_10_1016_j_transproceed_2017_01_055
crossref_primary_10_1097_LVT_0000000000000145
crossref_primary_10_1080_17474124_2021_1823213
crossref_primary_10_2217_fon_2021_1635
crossref_primary_10_1177_1526924816664083
crossref_primary_10_1097_SLA_0000000000005295
crossref_primary_10_3390_cancers16020259
crossref_primary_10_3390_cancers14030630
crossref_primary_10_1016_j_ijrobp_2021_10_006
crossref_primary_10_1097_TXD_0000000000000921
crossref_primary_10_4103_tcmj_tcmj_247_20
crossref_primary_10_3310_hta24480
crossref_primary_10_1016_j_jpi_2023_100360
crossref_primary_10_1007_s00261_021_03192_8
crossref_primary_10_14218_JCTH_2021_00125
crossref_primary_10_1016_j_intimp_2020_106188
crossref_primary_10_3390_cancers14205114
crossref_primary_10_1002_acm2_12113
crossref_primary_10_1097_TP_0000000000003140
crossref_primary_10_1080_02656736_2020_1834154
crossref_primary_10_1159_000521596
crossref_primary_10_1007_s12328_022_01643_3
crossref_primary_10_1097_TXD_0000000000000814
crossref_primary_10_3748_wjg_v25_i37_5630
crossref_primary_10_3748_wjg_v28_i34_4929
crossref_primary_10_1097_TP_0000000000003434
crossref_primary_10_5500_wjt_v10_i11_297
crossref_primary_10_1016_j_hbpd_2023_12_001
crossref_primary_10_1097_MEG_0000000000001448
crossref_primary_10_52604_alt_22_0018
crossref_primary_10_1111_ctr_13703
crossref_primary_10_1111_liv_14346
crossref_primary_10_1111_liv_14621
crossref_primary_10_3346_jkms_2018_33_e283
crossref_primary_10_1097_TP_0000000000004487
crossref_primary_10_12998_wjcc_v8_i13_2758
crossref_primary_10_3390_cancers14112662
crossref_primary_10_1016_j_hbpd_2020_06_002
crossref_primary_10_3390_jcm11154389
crossref_primary_10_1038_s41366_023_01367_5
crossref_primary_10_3390_ijms21165791
crossref_primary_10_1007_s12072_023_10629_3
crossref_primary_10_1097_FTD_0000000000001119
crossref_primary_10_3390_cancers15102729
crossref_primary_10_1002_cam4_5106
crossref_primary_10_1111_apt_15253
crossref_primary_10_3390_cancers15235593
crossref_primary_10_3350_cmh_2021_0217
crossref_primary_10_3390_jcm12072560
crossref_primary_10_1155_2021_7776389
crossref_primary_10_31083_j_jmcm_2019_02_9161
crossref_primary_10_4254_wjh_v15_i4_460
crossref_primary_10_3390_ijms241713547
crossref_primary_10_1016_j_dld_2023_05_026
crossref_primary_10_1016_S1499_3872_16_60097_8
crossref_primary_10_1007_s11901_024_00666_3
crossref_primary_10_1007_s12672_024_01083_0
crossref_primary_10_3390_diagnostics13050981
crossref_primary_10_1007_s00432_017_2507_2
crossref_primary_10_1007_s12029_021_00767_y
crossref_primary_10_1002_jcb_28128
crossref_primary_10_11569_wcjd_v27_i23_1407
crossref_primary_10_3390_gidisord6030040
crossref_primary_10_1016_j_ctrv_2019_05_004
crossref_primary_10_3390_life13071562
crossref_primary_10_1016_j_aohep_2021_100654
crossref_primary_10_1097_TP_0000000000002532
crossref_primary_10_1177_17562848221086126
crossref_primary_10_1016_j_jceh_2019_09_007
crossref_primary_10_12677_ACM_2019_93047
crossref_primary_10_4251_wjgo_v13_i8_845
crossref_primary_10_1111_liv_14736
crossref_primary_10_4254_wjh_v11_i3_261
crossref_primary_10_1002_hep4_1846
crossref_primary_10_3390_curroncol30060421
crossref_primary_10_1016_j_surg_2018_10_024
crossref_primary_10_1007_s00259_021_05328_w
crossref_primary_10_1002_cam4_5123
crossref_primary_10_1016_j_hpb_2016_06_010
crossref_primary_10_1111_tri_13897
crossref_primary_10_1016_j_transproceed_2019_12_001
crossref_primary_10_1097_MD_0000000000014368
crossref_primary_10_1111_ctr_13634
crossref_primary_10_3389_fnut_2023_1127913
crossref_primary_10_37174_2587_7593_2023_6_3_81_89
crossref_primary_10_1016_j_transproceed_2022_09_031
crossref_primary_10_1007_s00270_021_02784_7
crossref_primary_10_1016_j_xocr_2022_100449
crossref_primary_10_3350_cmh_2021_0038
Cites_doi 10.1016/j.gcb.2009.02.036
10.1159/000357801
10.1002/bjs.5198
10.1016/j.ejso.2009.10.001
10.1097/TP.0b013e3181c3c540
10.1016/j.transproceed.2007.06.042
10.1111/ctr.12286
10.3348/kjr.2007.8.4.320
10.1038/aps.2010.124
10.1159/000343043
10.1016/j.athoracsur.2007.10.065
10.1007/s00268-012-1533-0
10.1111/j.1600-6143.2009.02860.x
10.1007/s00423-013-1114-1
10.1007/s10654-010-9491-z
10.1002/jmri.22326
10.1002/lt.22047
10.1053/j.gastro.2004.09.041
10.1016/j.transproceed.2010.02.014
10.1016/j.canlet.2014.11.032
10.6002/ect.2012.0085
10.1038/17401
10.1056/NEJM199603143341104
10.1007/s12029-010-9196-2
10.1016/j.jhep.2010.07.049
10.1111/j.1432-2277.2012.01540.x
10.1159/000319548
10.1097/meg.0000000000000073
10.1007/PL00009947
10.1002/hep.23437
10.1002/lt.21953
10.7182/pit2014632
10.1016/j.jhep.2013.02.026
10.1016/S1470-2045(08)70284-5
10.1002/lt.24042
10.1111/ctr.12150
10.3748/wjg.v16.i43.5518
10.1097/TP.0b013e3181daac69
10.1002/lt.20128
10.1136/bmj.39489.470347.AD
10.1016/j.cgh.2014.08.013
10.3748/wjg.v12.i35.5729
10.1097/MEG.0b013e328359e550
10.1111/j.1743-7563.2011.01425.x
10.1016/S1470-2045(11)70175-9
10.1245/s10434-014-4273-6
10.1111/ctr.12090
10.1053/j.gastro.2007.04.061
10.1016/j.dld.2011.12.009
10.1002/lt.22434
10.1016/j.ejca.2012.12.027
10.1053/j.gastro.2012.05.052
10.1016/j.transproceed.2005.03.013
10.1245/s10434-010-0999-y
10.1007/s00534-012-0528-4
10.1016/j.transproceed.2009.06.083
10.1016/j.transproceed.2012.06.046
10.12659/AOT.890505
10.1002/lt.20391
10.1111/j.1600-6143.2011.03689.x
10.4161/cbt.8.7.7902
10.1371/journal.pmed.1000097
10.1200/JCO.2010.28.7805
10.1136/bmj.d5928
10.1093/jjco/hyq055
10.1016/j.transproceed.2013.07.032
10.1016/j.jhep.2013.03.029
10.1016/j.ejca.2008.10.026
10.1002/hep.22693
10.1016/j.lungcan.2010.02.014
10.3748/wjg.14.5717
10.1053/jhep.2002.36807
10.1016/j.transproceed.2011.06.063
10.1700/950.10394
10.1177/1534735409359772
10.1097/SLA.0b013e31820508f1
10.1016/j.ejcts.2011.05.052
10.1177/000313481408000723
10.1111/j.1440-1746.2008.05672.x
10.1001/archsurg.2007.39
10.1007/s00268-011-1146-z
10.1016/j.jhep.2013.10.030
10.1016/j.transproceed.2013.10.035
10.1002/lt.22361
10.1016/j.jhep.2010.01.025
10.1111/j.1432-2277.2012.01562.x
10.1016/j.transproceed.2012.09.022
10.1016/j.jvir.2007.07.017
10.1016/j.jhep.2010.08.038
10.1053/jlts.2002.34892
10.1016/j.jvir.2009.11.006
10.1016/j.transproceed.2004.02.028
ContentType Journal Article
Copyright The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. 2015
Copyright_xml – notice: The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. 2015
DBID 2RA
92L
CQIGP
W91
~WA
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
DOI 10.3748/wjg.v21.i39.11185
DatabaseName 中文科技期刊数据库
中文科技期刊数据库-CALIS站点
维普中文期刊数据库
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic


MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review
EISSN 2219-2840
EndPage 11198
ExternalDocumentID 10_3748_wjg_v21_i39_11185
26494973
90888889504849535157485051
Genre Journal Article
Review
GroupedDBID ---
123
29R
2B.
2C~
2RA
2WC
36B
53G
5VR
8WL
92F
92I
92L
93N
93R
AAKDD
ACGFO
AENEX
AFUIB
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CQIGP
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FA0
FRP
GX1
HYE
M~E
OK1
P2P
RNS
RPM
SV3
TCJ
TGQ
TR2
W91
WFFXF
XSB
~WA
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c509t-f9b41e7bd062f5d96804421b416fa741af46ec19823bed72a022f6d2cee14c063
IEDL.DBID RPM
ISSN 1007-9327
IngestDate Fri Sep 01 02:20:21 EDT 2023
Fri Apr 12 08:50:09 EDT 2024
Thu Nov 21 20:42:45 EST 2024
Thu May 23 23:22:16 EDT 2024
Wed Feb 14 10:21:14 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 39
Keywords Trans-arterial chemoembolization
Tumor recurrence
Sorafenib
Recurrent hepatocellular carcinoma
Surgical resection
Systematic review
Liver transplantation
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c509t-f9b41e7bd062f5d96804421b416fa741af46ec19823bed72a022f6d2cee14c063
Notes AIM: To investigate the efficacy(survival) and safety of treatments for recurrent hepatocellular carcinoma(HCC) in liver transplantation(LT) patients.METHODS: Literature search was performed on available online databases without a time limit until January 2015. Clinical studies describing survival after HCC recurrence in LT patients were retrieved for a fulltext evaluation. A total of 61 studies were selected: 13 case reports, 41 retrospective case series, and 7 retrospective comparative studies.RESULTS: Based on all included studies, the mean HCC recurrence rate was 16% of all LTs for HCC. A total of 1021 LT patients experienced HCC recurrence. The median time from LT to HCC recurrence was 13 mo(range 2-132 mo). The majority of patients(67%) presented with HCC extra-hepatic recurrences, involving lung, bone, adrenal gland, peritoneal lymph nodes, and rarely the brain. Overall survival after HCC recurrence was 12.97 mo. Surgical resection of localized HCC recurrence and Sorafenib for controlling systemic spread of HCC recurrence were associated with the higher survival rates(42 and 18 mo, res-pectively). However, Sorafenib, especially when combined with m TOR, was frequently associated with severe side effects that required dose reduction or discontinuation CONCLUSION: Management of recurrent HCC in LT patients is challenging and associated with poor prognosis independently of the type of treatment.
Nicola de’Angelis;Filippo Landi;Maria Clotilde Carra;Daniel Azoulay;Unit of Digestive, Hepato-Pancreato-Biliary Surgery, and Liver Transplantation, Henri-Mondor Hospital;Inserm, Unité 4394-MACBEth, 94010 Créteil, France;Department of Advanced Biomedical Sciences, University Federico Ⅱ of Naples;University Paris 7, Denis Diderot, Rothschild Hospital;Inserm, Unité 955-IMRB, 94010 Créteil, France
Recurrent hepatocellular carcinoma;Liver transplan
SourceType-Scholarly Journals-1
ObjectType-Feature-4
ObjectType-Undefined-1
content type line 23
ObjectType-Review-2
ObjectType-Article-3
Author contributions: de’Angelis N and Azoulay D were at the origin of the work; de’Angelis N and Carra MC performed the systematic review of the literature (search, evaluation, selection, and quality assessment of the articles), data extraction, data analysis, and manuscript drafting; Landi F was the third blind reviewer and participated at the manuscript drafting and corrections; Azoulay D contributed at the final version of the manuscript with corrections and criticism.
Telephone: +33-1-49812348 Fax: +33-1-49812432
Correspondence to: Nicola de’Angelis, MD, PhD, Unit of Digestive, Hepato-Pancreato-Biliary Surgery, and Liver Transplantation, Henri-Mondor Hospital, Université Paris Est - UPEC, 51, Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. nic.deangelis@yahoo.it
OpenAccessLink https://doi.org/10.3748/wjg.v21.i39.11185
PMID 26494973
PQID 1727439519
PQPubID 23479
PageCount 14
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4607916
proquest_miscellaneous_1727439519
crossref_primary_10_3748_wjg_v21_i39_11185
pubmed_primary_26494973
chongqing_primary_90888889504849535157485051
PublicationCentury 2000
PublicationDate 2015-10-21
PublicationDateYYYYMMDD 2015-10-21
PublicationDate_xml – month: 10
  year: 2015
  text: 2015-10-21
  day: 21
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World Journal of Gastroenterology
PublicationYear 2015
Publisher Baishideng Publishing Group Inc
Publisher_xml – name: Baishideng Publishing Group Inc
References 25148760 - Clin Gastroenterol Hepatol. 2015 Mar;13(3):594-601.e1
11941967 - Hepatogastroenterology. 2002 Jan-Feb;49(43):249-51
24919730 - Prog Transplant. 2014 Jun;24(2):142-5
25371243 - Liver Transpl. 2015 Feb;21(2):187-94
23485231 - Eur J Cancer. 2013 Apr;49(6):1374-403
18837090 - World J Gastroenterol. 2008 Oct 7;14(37):5717-22
23567081 - J Hepatol. 2013 Jul;59(1):3-5
23139662 - Case Rep Oncol. 2012 Sep;5(3):506-10
18436948 - BMJ. 2008 Apr 26;336(7650):924-6
20353879 - Lung Cancer. 2010 Dec;70(3):295-300
22750200 - Gastroenterology. 2012 Oct;143(4):986-94.e3; quiz e14-5
19715866 - Transplant Proc. 2009 Jul-Aug;41(6):2181-3
19073403 - Hepatobiliary Pancreat Dis Int. 2008 Dec;7(6):590-4
20652370 - Eur J Epidemiol. 2010 Sep;25(9):603-5
21102481 - Acta Pharmacol Sin. 2010 Dec;31(12):1643-8
17570226 - Gastroenterology. 2007 Jun;132(7):2557-76
21932373 - Liver Transpl. 2012 Jan;18(1):45-52
19276683 - Cancer Biol Ther. 2009 Apr;8(7):585-90
23500153 - J Hepatol. 2013 Jul;59(1):59-66
15964374 - Transplant Proc. 2005 Jun;37(5):2185-7
24034033 - Transplant Proc. 2013 Sep;45(7):2726-8
24694739 - Eur J Gastroenterol Hepatol. 2014 May;26(5):577-8
24975583 - Ann Transplant. 2014;19:309-16
9683751 - J Hepatobiliary Pancreat Surg. 1998;5(1):29-34
23758296 - Clin Transplant. 2013 Jul-Aug;27(4):555-61
15048797 - Liver Transpl. 2004 Apr;10(4):534-40
22008217 - BMJ. 2011;343:d5928
18003999 - J Vasc Interv Radiol. 2007 Nov;18(11):1451-3
22047762 - Lancet Oncol. 2012 Jan;13(1):e11-22
19398289 - Gastroenterol Clin Biol. 2009 May;33(5):361-9
20308087 - Integr Cancer Ther. 2010 Mar;9(1):100-4
24372624 - Clin Transplant. 2014 Jan;28(1):141-8
21688382 - Liver Transpl. 2011 Oct;17 Suppl 2:S162-6
22710887 - J Hepatobiliary Pancreat Sci. 2013 Mar;20(3):342-7
25444925 - Cancer Lett. 2015 Feb 1;357(1):47-54
20952085 - J Hepatol. 2011 Jan;54(1):182-3
15838913 - Liver Transpl. 2005 May;11(5):497-503
16329080 - Br J Surg. 2006 Jan;93(1):11-8
24987900 - Am Surg. 2014 Jul;80(7):680-4
21831154 - Am J Transplant. 2011 Oct;11(10):2031-5
12407579 - Hepatology. 2002 Nov;36(5 Suppl 1):S74-83
19175825 - J Gastroenterol Hepatol. 2009 May;24(5):800-5
10028970 - Nature. 1999 Feb 11;397(6719):530-4
15508093 - Gastroenterology. 2004 Nov;127(5 Suppl 1):S268-76
24091908 - Langenbecks Arch Surg. 2013 Dec;398(8):1123-8
12200775 - Liver Transpl. 2002 Sep;8(9):765-74
20494947 - Jpn J Clin Oncol. 2010 Aug;40(8):768-73
22882364 - Transpl Int. 2012 Nov;25(11):1158-64
20021481 - Am J Transplant. 2009 Dec;9(12):2851-4
19152426 - Hepatology. 2009 Mar;49(3):832-8
20606568 - Transplantation. 2010 Jul 15;90(1):98-9
17673843 - Korean J Radiol. 2007 Jul-Aug;8(4):320-7
24610283 - Gulf J Oncolog. 2014 Jan;1(15):12-8
17007031 - World J Gastroenterol. 2006 Sep 21;12(35):5729-32
20304217 - Transplant Proc. 2010 Mar;42(2):660-2
20714941 - J Gastrointest Cancer. 2011 Mar;42(1):50-3
15110588 - Transplant Proc. 2004 Apr;36(3):545-6
24216445 - J Hepatol. 2014 Mar;60(3):681
21884437 - Asia Pac J Clin Oncol. 2011 Sep;7(3):258-69
21591009 - J Magn Reson Imaging. 2011 Jun;33(6):1399-405
20679622 - J Clin Oncol. 2010 Sep 1;28(25):3994-4005
20440777 - Liver Transpl. 2010 May;16(5):678-84
23383956 - Clin Transplant. 2013 Mar-Apr;27(2):E192-8
21727012 - Eur J Cardiothorac Surg. 2012 Feb;41(2):376-82
23044808 - Eur J Gastroenterol Hepatol. 2013 Feb;25(2):180-6
25436316 - Hepatogastroenterology. 2014 Jul-Aug;61(133):1387-92
22994652 - Transpl Int. 2013 Feb;26(2):109-18
22974889 - Transplant Proc. 2012 Sep;44(7):1989-91
23146514 - Transplant Proc. 2012 Nov;44(9):2754-6
21294289 - Ann Surg. 2011 Jan;253(1):166-72
20347502 - J Hepatol. 2010 May;52(5):771-5
17889173 - Transplant Proc. 2007 Sep;39(7):2308-10
19097774 - Eur J Cancer. 2009 Jan;45(2):228-47
21911167 - Transplant Proc. 2011 Sep;43(7):2800-5
21989430 - Tumori. 2011 Jul-Aug;97(4):436-41
25472651 - Ann Surg Oncol. 2015 Jul;22(7):2286-94
19938137 - Liver Transpl. 2009 Dec;15(12):1834-42
21111506 - J Hepatol. 2011 Feb;54(2):396-8
20187107 - Hepatology. 2010 Apr;51(4):1237-43
20116286 - J Vasc Interv Radiol. 2010 Mar;21(3):333-8
20204531 - Ann Surg Oncol. 2010 Sep;17(9):2283-9
21086573 - World J Gastroenterol. 2010 Nov 21;16(43):5518-22
22265328 - Dig Liver Dis. 2012 May;44(5):432-7
19857941 - Eur J Surg Oncol. 2010 Mar;36(3):275-80
19621072 - PLoS Med. 2009 Jul 21;6(7):e1000097
18283144 - Arch Surg. 2008 Feb;143(2):182-8; discussion 188
22411088 - World J Surg. 2012 Jul;36(7):1592-602
21071991 - Oncology. 2010;79(1-2):62-6
20098287 - Transplantation. 2010 Jan 27;89(2):227-31
24507059 - Transplant Proc. 2014 Jan-Feb;46(1):241-4
19058754 - Lancet Oncol. 2009 Jan;10(1):35-43
18222234 - Ann Thorac Surg. 2008 Feb;85(2):412-5
7549059 - Clin Transplant. 1995 Jun;9(3 Pt 1):190-6
24575010 - Case Rep Oncol. 2014 Jan 10;7(1):18-22
21597889 - World J Surg. 2011 Sep;35(9):2058-62
8594428 - N Engl J Med. 1996 Mar 14;334(11):693-9
23216564 - Exp Clin Transplant. 2012 Dec;10(6):531-43
ref57
ref56
ref59
ref58
ref53
ref52
ref55
ref54
ref51
ref50
ref46
ref45
ref48
ref47
ref42
ref41
ref44
ref43
ref49
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref40
ref35
ref34
ref37
ref36
ref31
ref30
ref33
ref32
ref39
ref38
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref13
ref12
ref15
ref14
ref97
ref96
ref11
ref10
ref98
ref17
ref16
ref19
ref18
ref93
ref92
ref95
ref94
ref91
ref90
ref89
ref86
ref85
ref88
ref87
ref82
ref81
ref84
ref83
ref80
ref79
ref78
ref75
ref74
ref77
ref76
ref2
ref1
ref71
ref70
ref73
ref72
ref68
ref67
ref69
ref64
ref63
ref66
ref65
ref60
ref62
ref61
References_xml – ident: ref11
  doi: 10.1016/j.gcb.2009.02.036
– ident: ref29
  doi: 10.1159/000357801
– ident: ref10
  doi: 10.1002/bjs.5198
– ident: ref24
– ident: ref50
  doi: 10.1016/j.ejso.2009.10.001
– ident: ref96
  doi: 10.1097/TP.0b013e3181c3c540
– ident: ref44
  doi: 10.1016/j.transproceed.2007.06.042
– ident: ref56
  doi: 10.1111/ctr.12286
– ident: ref49
  doi: 10.3348/kjr.2007.8.4.320
– ident: ref80
  doi: 10.1038/aps.2010.124
– ident: ref39
  doi: 10.1159/000343043
– ident: ref38
  doi: 10.1016/j.athoracsur.2007.10.065
– ident: ref30
– ident: ref83
  doi: 10.1007/s00268-012-1533-0
– ident: ref35
  doi: 10.1111/j.1600-6143.2009.02860.x
– ident: ref78
  doi: 10.1007/s00423-013-1114-1
– ident: ref21
  doi: 10.1007/s10654-010-9491-z
– ident: ref51
  doi: 10.1002/jmri.22326
– ident: ref57
  doi: 10.1002/lt.22047
– ident: ref8
  doi: 10.1053/j.gastro.2004.09.041
– ident: ref61
  doi: 10.1016/j.transproceed.2010.02.014
– ident: ref94
  doi: 10.1016/j.canlet.2014.11.032
– ident: ref18
  doi: 10.6002/ect.2012.0085
– ident: ref90
  doi: 10.1038/17401
– ident: ref7
  doi: 10.1056/NEJM199603143341104
– ident: ref28
  doi: 10.1007/s12029-010-9196-2
– ident: ref97
  doi: 10.1016/j.jhep.2010.07.049
– ident: ref76
  doi: 10.1111/j.1432-2277.2012.01540.x
– ident: ref48
  doi: 10.1159/000319548
– ident: ref53
  doi: 10.1097/meg.0000000000000073
– ident: ref75
  doi: 10.1007/PL00009947
– ident: ref93
  doi: 10.1002/hep.23437
– ident: ref92
  doi: 10.1002/lt.21953
– ident: ref25
  doi: 10.7182/pit2014632
– ident: ref79
  doi: 10.1016/j.jhep.2013.02.026
– ident: ref16
  doi: 10.1016/S1470-2045(08)70284-5
– ident: ref88
  doi: 10.1002/lt.24042
– ident: ref81
  doi: 10.1111/ctr.12150
– ident: ref37
  doi: 10.3748/wjg.v16.i43.5518
– ident: ref26
  doi: 10.1097/TP.0b013e3181daac69
– ident: ref55
  doi: 10.1002/lt.20128
– ident: ref22
  doi: 10.1136/bmj.39489.470347.AD
– ident: ref5
  doi: 10.1016/j.cgh.2014.08.013
– ident: ref46
– ident: ref31
  doi: 10.3748/wjg.v12.i35.5729
– ident: ref66
  doi: 10.1097/MEG.0b013e328359e550
– ident: ref47
  doi: 10.1111/j.1743-7563.2011.01425.x
– ident: ref6
  doi: 10.1016/S1470-2045(11)70175-9
– ident: ref52
– ident: ref72
  doi: 10.1245/s10434-014-4273-6
– ident: ref77
– ident: ref82
  doi: 10.1111/ctr.12090
– ident: ref4
  doi: 10.1053/j.gastro.2007.04.061
– ident: ref63
  doi: 10.1016/j.dld.2011.12.009
– ident: ref45
  doi: 10.1002/lt.22434
– ident: ref2
  doi: 10.1016/j.ejca.2012.12.027
– ident: ref14
  doi: 10.1053/j.gastro.2012.05.052
– ident: ref32
  doi: 10.1016/j.transproceed.2005.03.013
– ident: ref59
  doi: 10.1245/s10434-010-0999-y
– ident: ref60
  doi: 10.1007/s00534-012-0528-4
– ident: ref36
  doi: 10.1016/j.transproceed.2009.06.083
– ident: ref62
  doi: 10.1016/j.transproceed.2012.06.046
– ident: ref41
  doi: 10.12659/AOT.890505
– ident: ref91
  doi: 10.1002/lt.20391
– ident: ref89
  doi: 10.1111/j.1600-6143.2011.03689.x
– ident: ref67
  doi: 10.4161/cbt.8.7.7902
– ident: ref19
  doi: 10.1371/journal.pmed.1000097
– ident: ref1
  doi: 10.1200/JCO.2010.28.7805
– ident: ref20
  doi: 10.1136/bmj.d5928
– ident: ref65
  doi: 10.1093/jjco/hyq055
– ident: ref74
  doi: 10.1016/j.transproceed.2013.07.032
– ident: ref98
  doi: 10.1016/j.jhep.2013.03.029
– ident: ref85
  doi: 10.1016/j.ejca.2008.10.026
– ident: ref17
  doi: 10.1002/hep.22693
– ident: ref69
  doi: 10.1016/j.lungcan.2010.02.014
– ident: ref64
– ident: ref71
  doi: 10.3748/wjg.14.5717
– ident: ref3
  doi: 10.1053/jhep.2002.36807
– ident: ref33
  doi: 10.1016/j.transproceed.2011.06.063
– ident: ref54
  doi: 10.1700/950.10394
– ident: ref86
  doi: 10.1177/1534735409359772
– ident: ref15
  doi: 10.1097/SLA.0b013e31820508f1
– ident: ref70
  doi: 10.1016/j.ejcts.2011.05.052
– ident: ref73
  doi: 10.1177/000313481408000723
– ident: ref84
  doi: 10.1111/j.1440-1746.2008.05672.x
– ident: ref87
  doi: 10.1001/archsurg.2007.39
– ident: ref42
  doi: 10.1007/s00268-011-1146-z
– ident: ref95
  doi: 10.1016/j.jhep.2013.10.030
– ident: ref43
  doi: 10.1016/j.transproceed.2013.10.035
– ident: ref12
  doi: 10.1002/lt.22361
– ident: ref23
  doi: 10.1016/j.jhep.2010.01.025
– ident: ref13
  doi: 10.1111/j.1432-2277.2012.01562.x
– ident: ref58
  doi: 10.1016/j.transproceed.2012.09.022
– ident: ref27
  doi: 10.1016/j.jvir.2007.07.017
– ident: ref34
  doi: 10.1016/j.jhep.2010.08.038
– ident: ref9
  doi: 10.1053/jlts.2002.34892
– ident: ref68
  doi: 10.1016/j.jvir.2009.11.006
– ident: ref40
  doi: 10.1016/j.transproceed.2004.02.028
SSID ssj0023352
Score 2.552296
SecondaryResourceType review_article
Snippet AIM: To investigate the efficacy(survival) and safety of treatments for recurrent hepatocellular carcinoma(HCC) in liver transplantation(LT) patients.METHODS:...
To investigate the efficacy (survival) and safety of treatments for recurrent hepatocellular carcinoma (HCC) in liver transplantation (LT) patients. Literature...
AIMTo investigate the efficacy (survival) and safety of treatments for recurrent hepatocellular carcinoma (HCC) in liver transplantation (LT)...
AIM: To investigate the efficacy (survival) and safety of treatments for recurrent hepatocellular carcinoma (HCC) in liver transplantation (LT) patients....
SourceID pubmedcentral
proquest
crossref
pubmed
chongqing
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 11185
SubjectTerms Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - secondary
Carcinoma, Hepatocellular - surgery
carcinoma;Liver
hepatocellular
Humans
Liver Neoplasms - mortality
Liver Neoplasms - pathology
Liver Neoplasms - surgery
Liver Transplantation - adverse effects
Liver Transplantation - mortality
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - pathology
Neoplasm Recurrence, Local - therapy
Niacinamide - adverse effects
Niacinamide - analogs & derivatives
Niacinamide - therapeutic use
Phenylurea Compounds - adverse effects
Phenylurea Compounds - therapeutic use
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Recurrent
Reoperation
Risk Factors
Survival Analysis
Systematic Reviews
Time Factors
transplan
Treatment Outcome
Title Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review
URI http://lib.cqvip.com/qk/84123X/201539/90888889504849535157485051.html
https://www.ncbi.nlm.nih.gov/pubmed/26494973
https://search.proquest.com/docview/1727439519
https://pubmed.ncbi.nlm.nih.gov/PMC4607916
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3BTtwwEB0BF7hUIGgJFGQkTlWzG3sdJ-GGEAghgTgUiVtkOw5stessENrf74yzWbpwI8fEtiI_2_Nsv5kBOJY5V-lIuFhUiYzlCLHQhvPYasm5ojyZkvydr2_U5Z28uk_vVyDtfWGCaN-a8cBPpgM_fgzaytnUDnud2PD2-kyqJENaM1yFVTS__RZ9vssiJ6JwxZlkMZKTrLvKpCgrw7-_HwZ_BB-McYDgHM8pbQ0SgkIWlDZ9Hdcb__CEFmPZRn0gnu_1k_8ZpItN-DJnkuy0--MtWHF-G8ybnOWFNTV7puN0CsDEHtHutA2d05PwlFnKIeSbqWYhSzibkD6DtSHU-UR3_kj-hJ2yt1DPrHNz2YG7i_NfZ5fxPI1CbJENtHFdGMldZqpEiTqtCpUnUgqOL1WtkVDoWipneZGLkXFVJjSa9VpVAs0nlxYpzFdY8413u8CMcryWtXW47cE2jElza3Nd5FRf6TSCn4tOLGdduIySlFT4FCkuFqRmRQaFYCDz4hH86Pt5URo3JYRViViViFWJWJUBqwiOeiRKnALUX9q75vWlJA6GvAq5aATfOmQWzfXwRpAtYbYoQOG1l7_gqAthtuejbO_TNfdhA-lVCPQq-HdYa59f3QFSmNYchiH7D5w58Ns
link.rule.ids 230,314,727,780,784,885,27924,27925,53791,53793
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwEB2VciiXCsRXgIKROCGyG3sdJ-mtqqgW6FYcWqk3y3acdtGu048U_j4zzmbLwo2cosSOIj_b82y_mQH4IEuu8onwqagzmcoJYmEs56kzknNFeTIl-TvPTtT0TH49z8-3IB98YaJo39n5KCyWozC_jNrKq6UbDzqx8ffZoVRZgbRm_AAe5hO8Gxbpq3UWuRHFQ86sSJGeFP1hJsVZGf_6cTH6Kfhojl0ER3lJiWuQElSyosTpOzjjhItrtBmbVuof6vm3gvIPk3T0GHZXXJId9P_8BLZ8eAr2XtByy9qG3dCGOoVgYpdoebqWdupJesocZREK7dKwmCecLUihwboY7Hxheo-ksM8O2H2wZ9Y7ujyDs6PPp4fTdJVIIXXIB7q0qazkvrB1pkST15UqMykFx4eqMUgpTCOVd7wqxcT6uhAGDXujaoEGlEuHJOY5bIc2-JfArPK8kY3zuPDBb1ibl86VpiqpvjJ5Ap_Wjaiv-oAZmrRUeFU5ThekZ0UOhWAg9-IJfBzaeV0alyWElUasNGKlESsdsUrg_YCExkFA7WWCb-9uNbEwZFbIRhN40SOz_twAbwLFBmbrAhRge_MN9rsYaHvVz179d813sDM9nR3r4y8n317DIyRbMeyr4G9gu7u583tIaDr7Nnbf323A9DA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKKwEXRFU-wleNxAmRTex1nIRbVVi1pa16oFJvlu3Y7aJdZ2lT-PvMOJttF27kmNhW5Df2PNvPM4R8EBWTxZi7lDe5SMUYsNCGsdRqwZjEPJkC7zufnMqDc3F0UVzcS_UVRfvWTEdhNh-F6VXUVi7mNht0YtnZyb6QeQm0Jls0PntAtooxGNmwUF-utfAqUTzozMsUKErZH2hirJXs94_L0S_ORlMwExjpFSavAVpQixqTpz-CWSdc_gS_se6p_qGff6so77mlyVPyZMkn6V7_39tkw4UdYu5ELTe09fQaN9UxDBO9Au_Ttbhbj_JTajGTUGjnmsZc4XSGKg3axYDnM93fSgqf6R69C_hM-8suz8j55Ov3_YN0mUwhtcAJutTXRjBXmiaX3BdNLatcCM7gpfQaaIX2QjrL6oqPjWtKrsG5e9lwcKJMWCAyz8lmaIN7SaiRjnnhrYPFD7RhTFFZW-m6wvpSFwn5tOpEteiDZijUU8FTFzBloKYVeBSAAfyLJeTj0M-r0rA0QawUYKUAKwVYqYhVQt4PSCgYCNhfOrj29kYhEwN2BYw0IS96ZFbNDfAmpFzDbFUAg2yvfwHbi8G2l7b26r9r7pKHZ18m6vjw9Ntr8hj4Voz8ytkbstld37q3wGk68y5a7x_zsvVD
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Managements+of+recurrent+hepatocellular+carcinoma+after+liver+transplantation%3A+A+systematic+review&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=de%E2%80%99Angelis%2C+Nicola&rft.au=Landi%2C+Filippo&rft.au=Carra%2C+Maria+Clotilde&rft.au=Azoulay%2C+Daniel&rft.date=2015-10-21&rft.pub=Baishideng+Publishing+Group+Inc&rft.issn=1007-9327&rft.eissn=2219-2840&rft.volume=21&rft.issue=39&rft.spage=11185&rft.epage=11198&rft_id=info:doi/10.3748%2Fwjg.v21.i39.11185&rft_id=info%3Apmid%2F26494973&rft.externalDBID=PMC4607916
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg